Alkermes ALKS LYBALVI — Revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Alkermes in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Alkermes’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Alkermes's lybalvi — revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Alkermes's LYBALVI — revenue?
- Alkermes (ALKS) reported LYBALVI — revenue of $92.36M in Q1 2026.
- How has Alkermes's LYBALVI — revenue changed year-over-year?
- Alkermes's LYBALVI — revenue increased by 31.9% year-over-year, from $70.02M to $92.36M.
- What is the long-term trend for Alkermes's LYBALVI — revenue?
- Over 4 years (2021 to 2025), Alkermes's LYBALVI — revenue has grown at a 154.9% compound annual growth rate (CAGR), from $8.22M to $346.69M.
- What does LYBALVI — revenue mean?
- The total net sales revenue earned from a specific pharmaceutical product after excluding taxes.
- How do you interpret LYBALVI — revenue?
- An increase indicates growing market demand, successful commercial execution, or expanded patient access, while a decrease may signal market saturation, increased competition, or loss of exclusivity.
- How does LYBALVI — revenue compare across companies?
- Comparable to product-specific net sales reported by other biotechnology and pharmaceutical firms, often benchmarked against therapeutic area peers.